T. Rowe Price Associates
SPRY icon

T. Rowe Price Associates’s ARS Pharmaceuticals SPRY Stock Holding History

T. Rowe Price Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Buy
50,579
+9,800
+24% +$84.3K ﹤0.01% 2723
2026
Q1 		$328K Buy
40,779
+6,991
+21% +$67K ﹤0.01% 2643
2025
Q4 		$394K Hold
33,788
– – ﹤0.01% 2501
2025
Q3 		$340K Buy
33,788
+6,397
+23% +$91.8K ﹤0.01% 2544
2025
Q2 		$478K Buy
27,391
+5,632
+26% +$81.3K ﹤0.01% 2325
2025
Q1 		$274K Buy
21,759
+1,841
+9% +$22.1K ﹤0.01% 2514
2024
Q4 		$211K Sell
19,918
-442,601
-96% -$6.2M ﹤0.01% 2654
2024
Q3 		$6.71M Buy
462,519
+446,799
+2,842% +$5.31M ﹤0.01% 1223
2024
Q2 		$134K Buy
+15,720
New +$140K ﹤0.01% 2697
2023
Q3 		– Sell
-16,537
Closed -$111K – 2912
2023
Q2 		$111K Buy
16,537
+4,936
+43% +$32.9K ﹤0.01% 2682
2023
Q1 		$76K Buy
+11,601
New +$89.1K ﹤0.01% 2733
2022
Q4 		– Sell
-26,500
Closed -$140K – 2976
2022
Q3 		$140K Sell
26,500
-139,700
-84% -$688K ﹤0.01% 2649
2022
Q2 		$705K Sell
166,200
-134,374
-45% -$469K ﹤0.01% 2063
2022
Q1 		$1.05M Buy
300,574
+900
+0.3% +$3.92K ﹤0.01% 1983
2021
Q4 		$2M Buy
+299,674
New +$2.44M ﹤0.01% 1712

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates's SPRY Position: Q2 2026 in Review

T. Rowe Price Associates increased its ARS Pharmaceuticals (SPRY) stake by 24% in Q2 2026, buying an estimated $84.3K and bringing the position to 50,579 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

T. Rowe Price Associates first reported a position in SPRY in Q4 2021 and has held it in 15 quarters since. The position peaked at $6.71M in Q3 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • T. Rowe Price Associates held 50,579 shares of ARS Pharmaceuticals worth $406K as of Q2 2026.
  • T. Rowe Price Associates bought 9,800 ARS Pharmaceuticals shares in Q2 2026, an estimated $84.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2723 holding.
  • T. Rowe Price Associates first reported a position in ARS Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • T. Rowe Price Associates's ARS Pharmaceuticals position peaked at $6.71M in Q3 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.